Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of a Nurse-led Program for the Prevention of Complications of Long-term Corticosteroid Therapy

NCT04909606 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-04-26
Last updated
2026-03-20

Condition(s) studied

Long Term Corticosteroid Therapy

Investigational drug(s) / intervention(s)

nurse-led prevention programCurrent care

nurse-led prevention program: Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment) The nurse-led prevention program will include: 1. A video explaining corticosteroids related adverse events and adequate preventive measures 2. An individual interview with the trained nurse 3. A consultation with a dietetician 4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant 5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician 6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures

Current care: Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician

Study summary

Long term corticosteroid therapy concerns 0.5 to 1% of the population and about 2.5% of elderly subjects. It is currently used as a cornerstone therapy in a wide variety of clinical contexts. The central problematic of prolonged corticosteroid therapy is the burden of adverse events associated with its long term use, including bone, metabolic and infectious complications.

The management of patients for whom the prescription of long term corticosteroid therapy is indicated should include an evaluation of the individual risk and implementation of the appropriate preventive measures. Such an approach should particularly include cortisonic osteoporosis prevention, infectious prevention including vaccination, prevention of adrenal insufficiency, promotion of physical activity, as well as dietary management.

In France, nurse-led prevention programs are highly developed for patients initiating immunosuppressive targeted therapies. Conversely, there are no dedicated nurse-led programs for patients starting prolonged corticosteroid therapy, for several historical and economical reasons.

The implementation of such programs is likely to be beneficial at different levels, including the reduction of the number of adverse events and improvement of health-related quality of life.

The main objective of the study is to determine the long-term benefit of a nurse-led prevention program among patients starting long-term corticosteroids therapy, compared to routine care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 or older * Initiation of corticosteroids within 30 days prior to inclusion * Estimated cumulative dosage of corticosteroids ≥ 2000 mg * Affiliated member of the social security system Exclusion Criteria: * Patients unable to give consent or unable to understand the protocol * A patient who is not 'or is no longer' able to communicate remotely by telephone could not 'or no longer' be included in the study. * Patients under guardianship * Previous exposure to long-term corticosteroids * Prescription of corticosteroids for the management of malignant neoplasms * Severe chronic renal failure with clearance of creatinine \< 30 ml/min. * History of organ transplantation * Pregnant or breastfeeding women

Primary outcome measure(s)

  • Determine the ability of a prevention program to reduce the burden of adverse events attributable to corticosteroid therapy — 12 months
    Glucocorticoid Toxicity Index Raw Score

Trial sites (5)

FacilityCityRegionStatus
CHU Brest Brest France Recruiting
CH La Rochelle La Rochelle France Recruiting
CH Le Mans Le Mans France Enrolling By Invitation
CH Le Puy en Velay Le Puy-en-Velay France Recruiting
CH de Morlaix Morlaix France Enrolling By Invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04909606 on ClinicalTrials.gov ↗ ← All trials in France